Join
Live feed
·
PRReleasevia Quantisnow
Black Diamond Therapeutics Inc. logo

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

ByQuantisnow·Wall Street's wire, on your screen.
BDTX· Black Diamond Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BDTX (Black Diamond Therapeutics Inc.) and more on Quantisnow.